

## Research Paper

# Yes-Associated Protein (Yap) Is Required for Early Embryonic Development in Zebrafish (*Danio Rerio*)

Jingying Hu<sup>1\*</sup>, Shuna Sun<sup>2\*</sup>, Qiu Jiang<sup>1</sup>, Shaoyang Sun<sup>1</sup>, Wei Wang<sup>2</sup>, Yonghao Gui<sup>2</sup>, Houyan Song<sup>1</sup>✉

1. Department of Biochemistry and Molecular Biology, Shanghai Medical School and Key Laboratory of Molecular Medicine, Ministry of Education, Fudan University, Shanghai 200032, PR China.
2. Children's Hospital, Fudan University, Shanghai 200032, PR China.

\* These authors contributed equally to this work.

✉ Corresponding author: Houyan Song, Department of Biochemistry and Molecular Biology, Shanghai Medical School and Key Laboratory of Molecular Medicine, Ministry of Education, Fudan University, Shanghai 200032, PR China.

© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (<http://creativecommons.org/licenses/by-nc-nd/3.0/>). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

Received: 2012.07.17; Accepted: 2013.02.26; Published: 2013.03.06

## Abstract

The hippo (Hpo) signaling pathway plays a critical role in regulation of organ size. The kinase cascade ultimately antagonizes the transcriptional co-activator Yki/YAP, which is a key regulator of cell proliferation and apoptosis. In this study, we performed a knocking down study using antisense morpholino (MO) reagents and found that zebrafish YAP, a key transcriptional co-activator of Hpo pathway, plays a critical role in early embryonic development. At the cellular level, *yap* inhibition increases apoptosis and decreases cell proliferation. Reduction of *yap* function severely delays several developmental events, including gastrulation, cardiogenesis and hematopoiesis. Knock-down of *yap* showed some evidence of ventralization, including reduction of dorsally expressed marker *gooseoid* (*gsc*), expansion of ventral marker *gata2*, disruption of the somites, and reduction in head size. Finally, we performed a preliminary analysis with real-time polymerase chain reaction (qPCR) for the candidate targets of zebrafish Hpo pathway. In conclusion, our results revealed that zebrafish *yap* coordinately regulates cell proliferation and apoptosis and is required for dorso-ventral axis formation, gastrulation, cardiogenesis, hematopoiesis, and somitogenesis.

Key words: Yes-Associated Protein, Yap, Zebrafish

## Introduction

The Hpo pathway, a novel signaling pathway defined in *Drosophila*, is extremely powerful in the regulation of growth and the suppression of tumors because of its ability to simultaneously inhibit cell proliferation and promote apoptosis [1-4]. Activation of the pathway induces a kinase cascade in which the Ste20-type kinase Hpo forms a complex with the WW-domain-containing adaptor protein Salvador (Sav). This complex then phosphorylates and activates the NDR family kinase Warts (Wts). After Wts binds to the Mob family protein Mats, it phosphorylates and inactivates the transcriptional co-activator Yorkie (Yki), which binds to the YEAD/TEF factor Scalloped

(Sd) and other possible transcription factors to regulate the transcription of cell-cycle and cell-death regulators such as *cyclin E* and *diap 1* [5, 6]. Like *Drosophila* studies, genetic and cell culture studies in mammalian cells have also linked the Hpo kinase cascade to the phosphorylation of YAP/TAZ, to two mammalian homologs of Yki, (transcriptional co-activator with PDZ-binding motif; also known as WWTR1), and to the regulation of growth [7-13].

The ease of creating genetic mosaics in *Drosophila* has exactly circumvented the hindrance of early lethality following gene depletion in the Hpo signal transduction pathway [4]. However, such efforts

cannot lead to complete understanding of its in vivo function in early embryonic development. Because of its semitransparent body, genetics and ease of manipulation, zebrafish are considered an ideal vertebrate model for the study of early development and cancer-related genes [14, 15]. Increasing amount of evidence suggest that the Hpo pathway might be evolutionarily conserved in zebrafish [16-20]. Bioinformatics analyses have indicated a considerable amount of evolutionary conservation between zebrafish and other species in the sequences, domains and motifs of several Hpo pathway components, including YAP/TAZ, LATS, Mats, and Fat [16-22]. Mats1, which regulates cell proliferation, apoptosis, and growth, is evolutionary conserved between zebrafish and drosophila [17]. Depletion of zebrafish *yap* ameliorates the changes in pronephros development caused by Fat1 knockdown [18]. To further elucidate the effects of the components of the hippo signaling pathway on early embryonic development, we investigated the role of *yap* in the zebrafish embryogenesis. We found that zebrafish *yap* regulates cell proliferation and survival and that it is required for normal formation of the dorsoventral axis.

## Results

### Embryos depleted of Yap exhibit a phenotype of delayed general development


To determine the role of *yap* during zebrafish embryogenesis, a translation-blocking morpholino (*yap*-MO) and a splicing-blocking morpholino (*yap*-MO(S)) were designed to knock down *yap* expression (Fig. 1A). The efficacy and specificity of *yap*-MO was recently confirmed [19]. We performed RT-PCR to demonstrate the activity of *yap*-MO(S). Our result showed that *yap* mRNA splicing was completely disrupted in embryos injected with 20 ng of the *yap*-MO(S). They either lacked exon2 or had an additional 71 bp fragment in intron2 (Fig. 1B). To produce the same phenotype, we used a much higher dose of *yap*-MO(S) than *yap*-MO. We also confirmed

the knockdown of endogenous Yap protein by Western blotting (Fig. 1C).


Almost all *yap*-MO-injected embryos showed a phenotype of delayed development, defined by comparison to age-matched control embryos (Fig. 2A-D and A'-D'). At 24 hpf, 51% of these abnormal *yap*-MO morphants (2-5 ng of *yap*-MO per embryo) showed moderate deviation from the morphological norm (Fig. 1D-c, c', and E), 26% with mild morphological abnormality (Fig. 1D-b, b', and E), and the rest 23% showed severe morphological deviations (Fig. 1D-d, d', and E). Mild morphants has indistinct heads and tails that bent toward the abdomen, moderate morphants had short bodies and curved trunks, and severe morphants had small trunks and completely indistinct bodies. Mortality was calculated at 48 hpf (Fig. 1E). No death was detected in the mild group (0/24). There was a 52% death rate in the moderate group (25/48) and a 64% death rate in the severe group (14/22). This effect was found to be MO-concentration-dependent (Table 1). Previous work has shown that embryos with reduced Yap exhibit marked increase in cell death of brain at 24 hpf [19]. In this study, we examined *yap*-MO-injected embryos at multiple time points during the first 24 h of development and compared them with their wild-type siblings (Fig. 2). At 6 hpf, when con-MO-injected or wild-type siblings reached the 60%-epiboly stage, the *yap* morphants had only developed to about the 50%-epiboly stage. The germ ring appeared thicker than that of wild-type (Fig. 2A and A'). At 10 hpf. The epiboly of siblings injected with con-MO was already complete but *yap* morphants showed only 60-80% epiboly (Fig. 2B and B'). By 18 hpf, the yolk extension of con-MO-injected siblings was clearly delimited from the yolk ball as the tail had straightened out, but the *yap* morphants were developmentally equivalent to wild-type or control embryos at about 14 hpf (Fig. 2C and C'). At 24 hpf, *yap*-MO-injected embryos displayed a shortened body axis and notable opacity in the head (Fig. 2D and D').

**Table 1.** Phenotypes observed in subjects exposed to different concentrations of *yap*-MO.

	n	Phenotype				Number of deaths at 48 hpf
		Normal	Mild	Moderate	Severe	
con-MO	100	96 (96.0%)	4 (4.0%)	0 (0.0%)	0 (0.0%)	2 (2.00%)
0.25-1 ng <i>yap</i> -MO	102	26 (25.5%)	55 (53.9%)	20 (19.6%)	1 (1%)	11 (10.78%)
2-5 ng <i>yap</i> -MO	99	0 (0.0%)	23 (23.2%)	51 (51.5%)	25 (25.3%)	43 (43.43%)
10-15 ng <i>yap</i> -MO	101	0 (0.0%)	2 (2.0%)	29 (28.7%)	70 (69.3%)	61 (60.39%)



**Fig 1. Analysis of *yap*-MOs and *yap* morphant phenotype.** A) Structure of zebrafish *yap* pre-mRNA (up) and mature mRNA (down). The black lines represent introns, the black rectangles represent exons, and the white rectangles represent untranslated regions (UTR). *yap*-MO(S) binds to the exon2-intron2 boundary and *yap*-MO binds to the 5'UTR near the ATG site. The blue rectangular dashed lines represent the WW-domain, which has here been omitted. B) RT-PCR analysis of *yap*-MO(S). RT-PCR was performed with a pair of primers (green arrows in (A), Table 1). C) Western blot analysis of *yap*-MO and *yap*-MO(S). Total proteins were extracted from 24 hpf zebrafish embryos. D) Bright-field images of 24 hpf embryos injected with con-MO (2-5 ng/embryo) (a and a') and *yap*-MO (2-5 ng/embryo) (b-d, b'-d'). At 24 hpf, *yap* morphants was divided into three groups according to their phenotypes: wild (b and b'), moderate (c and c') and severe (d and d'). D) The horizontal bars show the distribution of phenotypes observed in (C), and the vertical bars represent the death rate of each group before 48 hpf.



**Fig 2. Phenotypes of *yap* morphant and rescued phenotype.** A–D) and A'–D') Bright-field images show *yap* morphants, all of which exhibited developmental delay. A''–D'') This phenotype could be partially rescued after injection of synthesized *yap*-mRNA.

### Both *zyap1* and *zyap2* partially rescued the phenotype of *yap* morphants

During sequencing of the expression vector of synthetic *yap*-mRNA, we found a splicing variant that encodes zebrafish Yap with the first WW-domain. Yap with two WW-domains, known previously as zebrafish Yap, is here designated as Yap2 and the new Yap, which has only one WW-domain, is here designated as Yap1. Yap1 differs from Yap 2 in that it lacks the WW domain encoded on fourth exon. Yap2 may be a splicing variant (Supplementary Material: Fig. S1). The fourth exon is downstream of and far away from the target region of *yap*-MO(S). This is why *yap*-MO(S) can disrupt normal splicing (Fig. 1A, B). We injected zebrafish *yap1* (*zyap1*) and *yap2* (*zyap2*) mRNA, both lacking the targeted 5'-UTR, into different individuals. The phenotypes of the resulting *yap* MO morphants were partially rescued by con injection of *yap* mRNA (Fig. 2A''–D''). We counted the number of both moderate and severe embryo in each group at 24 hpf and found no obvious differences between *yap1* and *yap2* with respect to rescue (Fig. 3).

### Both cell survival and proliferation are defective in *yap* morphant embryos

Yki/YAP is a potent promoter of cell survival and proliferation in drosophila and a variety of cultured mammalian cells [1-4, 7-12], and is inhibited by Hpo signaling. To determine whether knocking down of *yap* increases the rate of apoptosis in developing

vertebrate embryos, a TUNEL assay was performed during the first 24 hpf (Fig. 4A-D and A'-D'). Both the control embryos and *yap* morphant embryos showed no or few TUNEL-positive signaling at 6 and 10 hpf (Fig. 4A, A', B, and B'). This may be because apoptotic cell death rarely occurs before 10 hpf. The *yap*-MO-injected embryos clearly exhibited increased apoptosis at 18 and 24 hpf, mainly in the head and caudal parts (Fig. 4C, C', D, and D'). In this way, knockdown of *yap* was found to result in increased cell death during embryonic development.


Then we determined whether cell proliferation in *yap* morphant embryos was defective. We used phosphohistone H3 (PH3) antibody staining to mark M-phase cells (Fig. 4E-H and E'-H'). At earlier stages (6, 10, and 18 hpf), the *yap* morphant embryos showed fewer mitotic cells than control or wild-type siblings (Fig. 4E, E', F, F', G, and G'). However, at 24 hpf, no significant difference in the PH3 staining was found between *yap* morphants and control embryos (Fig. 4H and H'). This is consistent with the results of our fluorescence-activated cell sorting (FACS) analysis (data not shown).

### Disrupted dorsoventral patterning in *yap*-depleted embryos


To determine whether *yap* inhibition affects markers of dorsoventral patterning during early stages of development, we examined the expression of various ventral and dorsal markers during early and late gastrula stages. There was no obvious dif-

ference in spatial expression of the ventral marker *bmp2b* between *yap* morphant and control embryos (Fig. 5A and A') [23], although there appeared to be a clear overall delay in the development of age-matched morphants relative to control and wild-type siblings. Defective epiboly movement during gastrulation may be the direct cause of the delayed development and similar spatial expression. The same may be true of the absence of dorsal markers *no tail (ntl)* (Fig. 5D, D',


E, and E') and the presence of *foxA2* (Fig. 5F and F') [24-26]. However, the control expression profiles of *gsc* and *gata2* during gastrulation showed reduced *gsc* expression in the prechordal plate and increased *gata2* expression in the ventral mesoderm rather than a simple delayed pattern (Fig. 5B, B', C, and C') [27-29]. In total, these data suggested that the reduction of *yap* disrupted dorsoventral marker expression during zebrafish gastrulation.



**Fig 3. No obvious differences between *zyap1* and *zyap2* with respect to rescue.** The percentage of abnormally developed embryos among control embryos, *yap* morphants, and *yap*-mRNA rescued morphants. The synthetic *yap*-mRNAs were found to partially rescue the *yap*-MO phenotype.



**Fig 4. Role of *yap* in regulation of apoptosis and proliferation during the first 24 hpf.** A–D) and A'–D') TUNEL staining indicates that knockdown of *yap* leads to increased cell death in the head and caudal parts. E–H) and E'–H') PH3 antibody staining suggests that *yap* inhibition results in reduced cell proliferation.



**Fig 5. Analysis of dorsoventral markers in *yap* morphants during gastrulation.** A–F) and A'–F') Whole-mount in situ hybridization of 6–9.5 hpf embryos injected with 2–5 ng con-MO (A–F) and *yap*-MO (A'–F') for *bmp2b* (A and A'), *gata2* (B and B'), *gsc* (C and C'), *ntl* (D, D', E and E'), and *foxA2* (F and F'). Embryos are shown laterally with ventral to the left (A–C and A'–C'), dorsally with anterior to the top (D, D', F and F'), and vegetally with ventral to the top (E and E').

### Effects of zebrafish *yap* on somitogenesis

Both the expression pattern of *yap* during somitogenesis and the shortened body axis of *yap*-depleted embryos indicate that *yap* function is critical for somatic development [19]. For this reason, we examined the expression of somatic marker *myoD* [30] in control and *yap* morphants. In situ hybridization showed that the level of *myoD* transcription might be up-regulated in *yap*-depleted embryos relative to control embryos (Fig. 6C and D). To confirm this result, we performed real-time PCR to quantify *myoD* expression level at 18hpf. We found a 2-fold increase of *myoD* mRNA level in *yap*-morphants compared with control (Fig. 6I). Despite the delayed onset of somatic development, somitogenesis proceeded faster in *yap* morphant embryos than that of the control, and *yap*-depleted embryos and control siblings reached the 18-somite stage at the same time (Fig. 6A–D). *titin* marks a somatic border in zebrafish embryos [31]. In control embryos, the dorsal and ventral portions of each myotome converge at the point where the horizontal myoseptum forms, and the somites take on a v-shape (Fig. 6E and G). In contrast, the somites in *yap*-MO-injected embryos appeared U-shaped (Fig. 6F and H) [32]. These results indicate that *yap* morphants have a higher expression level of *myoD*.

### Delayed cardiogenesis and hematopoiesis in *yap*-MO-injected embryos

Knockdown of *yap* causes developmental delay of cardiogenesis and hematopoiesis. In situ hybridization at 24 hpf with cardiac-specific markers *nkx2.5* and *titin* has demonstrated that the heart primordia in *yap*-MO-injected embryo forms a shallow cone with its apex raised dorsally around the lumen, but the

primordia of control embryos had already transformed into a linear tube (Fig. 7A, A', B, and B') [30, 33]. However, there was no observable difference in the timing of blood vessel development between *yap* morphants and control embryos, as assessed using the vascular marker *flk-1* (Fig. 7C and C') [34].

Erythrocytes in 30 hpf and 52 hpf embryos were identified by o-dianisidine staining (Fig. 8I), in which the presence of hemoglobin in erythrocytes was shown by a brown color after staining [35]. *yap*-MO embryos showed no red blood cells (RBC) at 30 hpf, but it was significantly recovered at 52 hpf. Further analysis of the *yap* morphant phenotype in Tg(*gata1*:EGFP) fish showed a clear delay in hematopoiesis after 28 hpf (Fig. 8II). Overall, our data indicate that *yap*-MO-injected embryos experience delayed cardiogenesis and hematopoiesis.


### RT-PCR and real-time PCR analysis for candidate target genes of the zebrafish Hpo signaling pathway

In *drosophila* and murine livers, several genes have been shown to be targets of the Hpo pathway. These include the cell-cycle regulator cyclin E (*ccne*) and cell-death regulator Diap1 [11,36]. To further investigate the mechanism by which the zebrafish Hpo pathway coordinately regulates cell proliferation and apoptosis, we searched the updated zebrafish proteome database ([http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&BLAST\\_PROGRAMS=blastp&PAGE\\_TYPE=BlastSearch&SHOW\\_DEFAULTS=on&LINK\\_LOC=blasthome](http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&BLAST_PROGRAMS=blastp&PAGE_TYPE=BlastSearch&SHOW_DEFAULTS=on&LINK_LOC=blasthome)) for candidate target genes of Hpo pathway. Based on sequence similarity, we selected six candidate downstream targets of Hpo pathway to validate using RT-PCR analysis, including *ccne1*, *ccne2*, *ccnd1*, *birc2*, *xiap*, and *ciapin*. We found


that the transcriptional level of *ccne2* was down-regulated in *yap*-depleted embryos (Fig. 9I). Real-time PCR was used to further confirm the results of RT-PCR (Fig. 9II). In addition, Hpo has been shown to phosphorylate and destabilized Diap1 through non-transcriptional processes [37, 38]. This is one possible explanation for the lack of marked changes in transcriptional level of these three possible regulators of cell death. In addition, undetected inhibitors of apoptosis may also have been involved in this process.

In mammalian cells, Lats can regulate the activ-


ity of TAZ, which shares sequence similarity to YAP and modulates mesenchymal differentiation [13]. In addition, TAZ-deficient zebrafish embryos were found to be defective in bone formation, as in our previous report on the phenotype of *yap*-MO-injected embryos [39]. For this reason, we determined expression level of TAZ in *yap*-morphants. We found that the same level of TAZ transcripts was present in *yap*-depleted embryos and in controls (Fig. 9I), ruling out the possibility that *yap*-MO produced these RT-PCR results and delayed phenotypes by reducing the level of TAZ.



**Fig 6. Effect of zebrafish *yap* on somitogenesis.** A–H) Whole-mount in situ hybridization for (A–D) *myoD* and (E–H) *titin* at 12, 18, and 24 hpf. A–D) Dorsal view with head to the left. E–H) Lateral view with head to the left. C, D, G, and H) The insets (bottom left corner) show the corresponding whole embryos. I) Real-time PCR result for *myoD* expression.




**Fig 7. Delayed cardiogenesis and normal vasculogenesis in *yap* morphants.** A–C and A'–C') Whole-mount in situ hybridization with *nkx2.5*, *titin*, and *flk-1*. A, A', B, and B') Anterior view with dorsal to the top. C and C') Lateral view with head to the left.



**Fig 8. Delayed hematopoiesis in yap morphants.** I) O-dianisidine staining shows that *yap*-MO embryos (B) have no red blood cells (RBC) at 30 hpf, with (D) significant recovery by 52 hpf. II) (A–J) Bright-field image and (A'–J') fluorescent image of live *Tg(gata1:EGFP)* embryos with (A, A', B, B', E, E', G, G', I, and I') *con*-MO and (C, C', D, D', F, F', H, H', J, and J') *yap*-MO. A–J and A'–J') Lateral view with head to the left, except in B, B', D, and D' (posterior view with dorsal to the top).





**Fig 9. RT-PCR and realtime-PCR analysis for candidate target genes of zebrafish Hpo signaling pathway.** I) For each gene (*ccne*, *ccne2*, *ccnd1*, *birc2*, *xiap*, *ciapin*, and *taz*), relative expression based on the RT-PCR is shown. Total mRNA was extracted from 18 hpf *yap*-MO and con-MO embryos, respectively. *ef-1a* was used as a loading control. II) Real-time-PCR result for *ccne2*, *ccnd1*, *birc2*, and *ciapin*.

## Discussion

Previous analysis of the sequence and conservation of the domains of core components of the Hpo pathway have facilitated in-depth investigations on the role of this signaling pathway during zebrafish early embryogenesis [16-20]. Our previous works have shown that *yap* knockdown caused morphological defects, including small heads, small eyes, and less cartilage in the branchial arches [19]. In this study, the difination of increased cell apoptosis and decreased cell proliferation may be the direct explanation of these morphological defects. Otherwise, we demonstrated that *yap*-mediated signaling establish specific dorsoventral patterning in zebrafish. Reduction of *yap* expression was also found to severely delay several developmental events, such as gastrulation, cardiogenesis, and hematopoiesis.

In this study, we tested the efficacy of both the translation-blocking *yap*-MO [19] and the splice-blocking *yap*-MO(S) (Fig.1B) by RT-PCR and Western blotting. Our results indicate that both MOs are effective to knock down the endogenous Yap protein, albeit we need to use a higher dose of the *yap* MO(S) (20 ng). Although we showed a disrupted *yap* mRNA-splicing in the 20 ng *yap* MO(S) group by RT-PCR, there was still a small amount of Yap protein present in the morphants as shown by western blot-

ting. It is likely that either our RT-PCR is not sensitive enough, or there are still some maternal Yap proteins present at this stage.

*Yap* gain of function causes shortened body axis and perturbed somatic and head morphology in both zebrafish and xenopus [20]. Because these late morphologies are similar to the *yap* knocking down phenotype, it can be difficult to determine whether the rescue is caused by overexpression of *yap* or knocking down of *yap*. The ratio of *yap* MO to *yap* mRNA needs more experimentation to be determined.

As previously reported, zebrafish Yap (Yap2), like mouse and human YAPs, contains two WW domains. We have identified the one WW domain splicing variant in zebrafish (Yap1). Zebrafish Yaps share significant sequence similarity with their homologues from chickens, mice, and humans (Supplementary Material: Fig. S2). This is especially true of the YAP2s of humans, mice, and zebrafish. Human YAP, which has two WW-domains, is a more potent transcriptional co-activator when compared with YAP with only one WW-domain [40]. In mice, both YAPs have two WW-domains. The first WW-domain has more pronounced affinity for the PPxY sequence, to which it binds more strongly than the second WW-domain does [41]. Although the functions of zebrafish Yap1 and each WW domain of Yap2 are still unknown, the determination of the precise differences

in signaling among *yap* splicing variants might be important.

During gastrulation, overall developmental delay increases the difficulty of analyzing defective dorsoventral patterns in *yap*-MO-injected embryos, but *yap* knockdown does reduce *gsc* expression and increase *gata2* expression. Confirmation of *gsc* down-regulation showed that *yap*-depleted embryos had up-regulated levels of *myoD* at 18 hpf with small heads. This is consistent with a previously described pattern in *gsc*-depleted xenopus embryos [42]. *yap*-depleted embryos seem to develop a ventralized morphology. During the cell fate specification phase of mouse trophectoderm (TE) development, the Hpo signaling pathway components Lats and Yap increase Tead4 activity, which induces Cdx2 expression by overcoming Oct3/4-mediated suppression [43]. Maternal zebrafish *Spg/Pou2/Oct4* controls the formation of the vertebrate dorsoventral axis and the *spg/pou2/oct4* mutant embryos develop a dorsalized morphology [44]. This is in contrast to our ventralized *yap* morphants, raising the possibility that Yap is required to establish dorsoventral patterning and that it does so by overcoming *Spg/Pou2/Oct4*-mediated suppression. Further elucidation of the mechanisms by which Yap controls dorsoventral axis formation are required for a more complete understanding of maternal control of embryonic development.

## Conclusion

In conclusion, zebrafish *yap* is required during early embryonic development. Reduction of *yap* leads to increased apoptosis, decreased proliferation, disrupted dorsoventral patterns and somitogenesis, as well as delayed cardiogenesis and hematopoiesis. Full identification of zYAP2 and further analysis of *yap* function are essential to understanding the function of the Hippo signaling pathway in zebrafish embryonic development.

## Materials and methods

### Fish care

The maintenance, breeding, and staging of zebrafish lines (AB and Shanghai) were performed as described previously [45, 46]. The *Tg(gata1:EGFP)* zebrafish line used in this study has been described elsewhere [47].

### Morpholinos and microinjection

Morpholino (MO) antisense oligonucleotides *yap*-MO (5'-CTCTTCTTCTATCCAACAGAAACC-3'), *yap*-MO(S) (5'-GCAACATTAACAACACTCACTTTA GGA-3'), and con-MO (5'-CCTCTTACCTCAGTTAC

AATTTATA-3') were obtained from Gene Tools, LLC (U.S.). One- and two-cell stage wildtype and *Tg(gata1:EGFP)* zebrafish embryos were injected with MOs (2–5 ng/embryo).

### Whole-mount TUNEL (terminal deoxynucleotidyl transferase mediated dUTP nick-end labeling) staining

Embryos were fixed in 4% PFA overnight at 4°C, then rinsed in PBS before proceeding with whole-mount TUNEL staining using an in situ Cell Death Detection Kit (Roche) according to the manufacturer's instructions.

### Whole-mount PH3 antibody staining

Mitotic cells were stained with a rabbit polyclonal anti phospho-histone H3 (Ser10) antibody (Cell Signaling Technology, Inc.). This was performed almost exactly as described in *The Zebrafish Book* at a dilution of 1:1000 [46]. The secondary antibody rhodamine (TRITC)-conjugated goat anti-rabbit IgG (Southern Biotech, U.S.) was diluted at 1:200.

### Whole-mount in situ hybridization

Digoxigenin-labeled antisense RNA probes for zebrafish *bmp2b*, *gsc*, *ntl*, *foxA2*, *gata2*, *myoD*, *titin*, *nkx2.5*, and *flk-1* were synthesized as described in previously published studies. Whole-mount in situ hybridization assay was performed as described [48].

### O-dianisidine staining for globin

Embryos were dechorionated and fixed in 4% PFA overnight at 4°C, then rinsed in PBS before proceeding with o-dianisidine staining. Fixed embryos were incubated in the staining buffer for 15 min in the dark. The staining buffer consisted of 0.6 mg/ml o-dianisidine (Sigma), 10 mM sodium acetate, 0.65% hydrogen peroxide, and 40% (v/v) ethanol.

### Reverse transcription-polymerase chain reaction (RT-PCR) and quantitative RT-PCR

Total RNA was extracted from zebrafish embryos using the Trizol reagent (Invitrogen) according to the manufacturer's protocol. Complimentary DNA synthesis was performed using a standard protocol with oligo-dT primers and Moloney murine leukemia virus reverse transcriptase (TaKaRa).

Primers (Table 2) were designed using PRIMER 3 software. PCR conditions were as follows: 95°C for 6 min; 30 cycles of 94°C for 30 s; 53°C for 30 s; and 72°C for 45 s; then 72°C for 10 min. The products were stored at 4°C. PCR products were separated on a 1.5% agarose gel.

Quantitative RT-PCR was performed on the 7500 (ABI) using the SYBR Premix Ex Taq (TaKaRa).

Measurements were performed in quadruplicate and normalized to the expression levels of Elf1- $\alpha$ . Fold changes values (X) were calculated using the following formula:  $X=2^{-\Delta\Delta Ct}$ . Bars indicate standard deviations. The PCR cycling conditions were as follows: 40 cycles of pre-denaturation at 95°C for 30 s, denaturation at 95°C for 5 s, and annealing and extension at 60°C for 34 s.

### Protein extraction and Western blot analysis

Total proteins were extracted from zebrafish embryos using RIPA solutions (Cell Signaling Technology, Inc.) according to the manufacturer's proto-

col. Protein concentrations were determined using the Bradford assay (BioRad). The proteins were then resolved on SDS/polyacrylamide gels and transferred to polyvinylidene fluoride membranes (Millipore). The membranes were probed with the following primary antibodies: YAP1 (Proteintech) and  $\beta$ -actin (Cell Signaling Technology, Inc.). After further washes, the membranes were incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies (Proteintech). Blots were developed using ECL (Millipore).

**Table 2.** Primer sequences.

Gene product	Gene bank ID	Upstream primers (5'>3')	Downstream primers (5'>3')	Product size (bp)
<i>ccne</i>	NM_130995.1	cgcagtgtgactgatgaat	actcgagtccccatgacaac	422
<i>ccne2</i>	NM_001002075.1	cacgacaagagcttcatcca	aggtttctctgcgagaactga	439
<i>ccnd1</i>	NM_131025.2	cccaccatctgaccaatacc	gaaaaagcaggaggacttg	410
<i>birc2</i>	NM_194395.2	catcataggggaaggaagca	ccttacaacacgcttgatt	438
<i>xiap</i>	NM_194396.2	atggcgaattggaatctgac	atggcgaattggaatctgac	408
<i>ciapin</i>	NM_001003738.1	tgctccagctatgactgtg	tgcatcaaaaagagcatctg	490
<i>taz</i>	NM_001037696.1	aacagtgggcccgtatcactc	tgagagcacaatccgacag	415
<i>ef-1a</i>	NM_131263.1	cttcgtccaatttcaggat	cagagactcgtggtgcatct	300
<i>myoD</i>	NM_131262.2	cgaggtctcgaatttttag	ctggggtccaagtcttcaa	273
<i>yap-sp</i>	NM_001139480.1	ggttgagaaaagctgccagac	tgggaaccttgcttactgg	583

## Supplementary Material

Fig.S1 - Fig.S2. <http://www.ijbs.com/v09p0267s1.pdf>

## Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China to Shuna Sun (30901472/H0204), from the National Natural Science Foundation of China to Yuexiang Wang (30600489), and from the Ph.D. Programs Foundation of the Ministry of Education of China to Shuna Sun (200802461111). We would like to thank Prof. Tingxi Liu for his very generous gift of *Tg (gata1:EGFP)* zebrafish. We would also like to thank Prof. Lei Zhang, Drs. Jian Yang and Dong Liu for their helpful advice, to thank Dr. Hui Xu for his advice on written English and the other members of Song and Tang's lab for providing technical assistance.

## Authors' contributions

JyH, QJ, and SnS conceived and designed the experiments. JyH, QJ, and SyS performed the experiments. SnS, WW, and YhG contributed reagents and materials. JyH and SnS wrote the manuscript. HyS

oversaw the experiments and helped to write the manuscript. All authors have read and approved the final manuscript.

## Competing Interests

The authors have declared that no competing interest exists.

## References

- Edgar BA. From cell structure to transcription: Hippo forges a new path. *Cell*. 2006; 124: 267- 273.
- Harvey K, Tapon N. The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. *Nat Rev Cancer*. 2007; 7: 182- 191.
- Pan D. Hippo signaling in organ size control. *Genes Dev*. 2007; 21: 886- 897.
- Saucedo LJ, Edgar BA. Filling out the Hippo pathway. *Nat Rev Mol Cell Biol*. 2007; 8: 613- 621.
- Wu S, Liu Y, Zheng Y, et al. The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. *Dev Cell*. 2008; 14: 388- 398.
- Zhang L, Ren F, Zhang Q, et al. The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. *Dev Cell*. 2008; 14: 377- 387.
- Hao Y, Chun A, Cheung K, et al. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. *J Biol Chem*. 2008; 283: 5496- 5509.
- Lee JH, Kim TS, Yang TH, et al. A crucial role of WW45 in developing epithelial tissues in the mouse. *EMBO J*. 2008; 27: 1231- 1242.
- Zhang J, Smolen GA, Haber DA. Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. *Cancer Res*. 2008; 68: 2789- 2794.

10. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev.* 2007; 21: 2747- 2761.
11. Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in *Drosophila* and mammals. *Cell.* 2007; 130: 1120- 1133.
12. Camargo FD, Gokhale S, Johnnidis JB, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. *Curr Biol.* 2007; 17: 2054- 2060.
13. Lei QY, Zhang H, Zhao B, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. *Mol Cell Biol.* 2008; 28: 2426- 2436.
14. Amatruda JF, Shepard JL, Stern HM, et al. Zebrafish as a cancer model system. *Cancer Cell.* 2002; 1: 229- 231.
15. Stern HM, Zon LI. Cancer genetics and drug discovery in the zebrafish. *Nat Rev Cancer.* 2003; 3: 533- 539.
16. Wang K, Degerny C, Xu M, et al. YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human disease. *Biochem Cell Biol.* 2009; 87: 77- 91.
17. Yuan Y, Lin S, Zhu Z, et al. The mob as tumor suppressor (*mats1*) gene is required for growth control in developing zebrafish embryos. *Int J Dev Biol.* 2009; 53: 525- 533.
18. Skouloudaki K, Puetz M, Simons M, et al. Scribble participates in Hippo signaling and is required for normal zebrafish pronephros development. *Proc Natl Acad Sci.* 2009; 106: 8579- 8584.
19. Jiang Q, Liu D, Gong Y, et al. *yap* is required for the development of brain, eyes, and neural crest in zebrafish. *Biochem Biophys Res Commun.* 2009; 384: 114- 119.
20. Gee ST, Milgram SL, Kramer KI, et al. Yes-associated protein 65 (YAP) expands neural progenitors and regulates Pax3 expression in the neural plate border zone. *Plos ONE.* 2011; 6: e20309
21. Nejigane S, Haramoto Y, Okuno M, et al. The transcriptional coactivators Yap and TAZ are expressed during early *Xenopus* development. *Int J Dev Biol.* 2011; 55: 121- 126.
22. Chen CH, Sun YH, Pei DS, et al. Comparative expression of zebrafish *Lats1* and *Lats2* and their implication in gastrulation movements. *Dev Dyn.* 2009; 238: 2850- 2859.
23. Xiong B, Rui Y, Zhang M, et al. *Tob1* controls dorsal development of zebrafish embryos by antagonizing maternal beta-catenin transcriptional activity. *Dev Cell.* 2006; 11: 225- 238.
24. Schulte-Merker S, van Eeden FJ, Halpern ME, et al. *no tail (ntl)* is the zebrafish homologue of the mouse *T (Brachyury)* gene. *Development.* 1994; 120: 1009- 1015.
25. Odenthal J, Nusslein-Volhard C. fork head domain genes in zebrafish. *Dev Genes Evol.* 1998; 208: 245-258.
26. McFarland KN, Warga RM, Kane DA. Genetic locus half baked is necessary for morphogenesis of the ectoderm. *Dev Dyn.* 2005; 233: 390-406.
27. Montero JA, Carvalho L, Wilsch-Brauninger M, et al. Shield formation at the onset of zebrafish gastrulation. *Development.* 2005; 132: 1187- 1198.
28. Inbal A, Topczewski J, Solnica-Krezel L. Targeted gene expression in the zebrafish prechordal plate. *Genesis.* 2006; 44: 584-588.
29. Read EM, Rodaway AR, Neave B, et al. Evidence for non-axial A/P patterning in the nonneural ectoderm of *Xenopus* and zebrafish pregastrula embryos. *Int J Dev Biol.* 1998; 42: 763- 774.
30. Weinberg ES, Allende ML, Kelly CS, et al. Developmental regulation of zebrafish *MyoD* in wild-type, *no tail* and *spadetail* embryos. *Development.* 1996; 122: 271-280.
31. Xu X, Meiler SE, Zhong TP, et al. Cardiomyopathy in zebrafish due to mutation in an alternatively spliced exon of *titin*. *Nat Genet.* 2002; 30: 205- 209.
32. van Eeden FJ, Granato M, Schach U, et al. Mutations affecting somite formation and patterning in the zebrafish, *Danio rerio*. *Development.* 1996; 123: 153- 164.
33. Yelon D. Cardiac patterning and morphogenesis in zebrafish. *Dev Dyn.* 2001; 222: 552- 563.
34. Fouquet B, Weinstein BM, Serluca FC, Fishman MC. Vessel patterning in the embryo of the zebrafish: guidance by notochord. *Dev Biol.* 1997; 183: 37-48.
35. Chu CY, Cheng CH, Chen GD, et al. The zebrafish erythropoietin: Functional identification and biochemical characterization. *FEBS Lett.* 2007; 581: 4265-4271
36. Huang J, Wu S, Barrera J, et al. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the *Drosophila* Homolog of YAP. *Cell.* 2005; 122: 421- 434.
37. Harvey KF, Pflieger CM, Hariharan IK. The *Drosophila* Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. *Cell.* 2003; 114: 457-467.
38. Pantalacci S, Tapon N, Leopold P. The Salvador partner Hippo promotes apoptosis and cell-cycle exit in *Drosophila*. *Nat Cell Biol.* 2003; 5: 921- 927.
39. Hong JH, Hwang ES, McManus MT, et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. *Science.* 2005; 309: 1074- 1078.
40. Komuro A, Nagai M, Navin NE, et al. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. *J Biol Chem.* 2003; 278: 33334- 33341.
41. Yagi R, Chen LF, Shigesada K, et al. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. *EMBO J.* 1999; 18: 2551- 2562.
42. Sander V, Reversade B, De Robertis EM. The opposing homeobox genes *Gooseoid* and *Vent1/2* self-regulate *Xenopus* patterning. *EMBO J.* 2007; 26: 2955- 2965.
43. Nishioka N, Inoue K, Adachi K, et al. The Hippo signaling pathway components *Lats* and *Yap* pattern *Tead4* activity to distinguish mouse trophoctoderm from inner cell mass. *Dev Cell.* 2009; 16: 398- 410.
44. Reim G, Brand M. Maternal control of vertebrate dorsoventral axis formation and epiboly by the POU domain protein *Spg/Pou2/Oct4*. *Development.* 2006; 133: 2757- 2770.
45. Kimmel CB, Ballard WW, Kimmel SR, et al. Stages of embryonic development of the zebrafish. *Dev Dyn.* 1995; 203: 253- 310.
46. Westerfield M. *The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Danio rerio)*, 4 edn. Oregon, USA: University of Oregon Press; 2000.
47. Dong M, Fu YF, Du TT, et al. Heritable and lineage-specific gene knockdown in zebrafish embryo. *PLoS One.* 2009; 4: e6125.
48. Thisse C, Thisse B. High-resolution in situ hybridization to whole-mount zebrafish embryos. *Nat. protoc.* 2008; 3: 59 - 69